PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma
PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma
Recruiting · NCT07209059 · Registry updated 2025-10-06Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma | Hemic and Lymphatic Diseases, Hodgkins lymphoma, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2025-10-06 | NCT07209059 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| National Research Center for Hematology, Russia | 5 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| National Medical Research Center for Hematology | Moscow | Russia | 2 |